Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2010 1
2014 1
2015 1
2016 4
2017 2
2018 2
2019 1
2020 2
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW. Mosely SI, et al. Among authors: valge archer v. Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6. Cancer Immunol Res. 2017. PMID: 27923825 Free article.
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.
Mellone M, Piotrowska K, Venturi G, James L, Bzura A, Lopez MA, James S, Wang C, Ellis MJ, Hanley CJ, Buckingham JF, Cox KL, Hughes G, Valge-Archer V, King EV, Beers SA, Jaquet V, Jones GDD, Savelyeva N, Sayan E, Parsons JL, Durant S, Thomas GJ. Mellone M, et al. Among authors: valge archer v. Cancer Res. 2022 Dec 16;82(24):4571-4585. doi: 10.1158/0008-5472.CAN-22-0435. Cancer Res. 2022. PMID: 36353752 Free PMC article.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: valge archer v. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. Staniszewska AD, et al. Among authors: valge archer v. Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022. Oncoimmunology. 2022. PMID: 35756843 Free PMC article.
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. Verma V, et al. Among authors: valge archer ve. Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23. Nat Immunol. 2021. PMID: 33230330 Free PMC article.
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma.
Egan D, Kreileder M, Nabhan M, Iglesias-Martinez LF, Dovedi SJ, Valge-Archer V, Grover A, Wilkinson RW, Slidel T, Bendtsen C, Barrett IP, Brennan DJ, Kolch W, Zhernovkov V. Egan D, et al. Among authors: valge archer v. Cancer Immunol Res. 2023 Aug 3;11(8):1125-1136. doi: 10.1158/2326-6066.CIR-22-0563. Cancer Immunol Res. 2023. PMID: 37229623 Free PMC article.
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.
Lopez-Pelaez M, Young L, Vazquez-Chantada M, Nelson N, Durant S, Wilkinson RW, Poon E, Gaspar M, Valge-Archer V, Smith P, Dovedi SJ. Lopez-Pelaez M, et al. Among authors: valge archer v. Oncoimmunology. 2022 Sep 13;11(1):2117321. doi: 10.1080/2162402X.2022.2117321. eCollection 2022. Oncoimmunology. 2022. PMID: 36117525 Free PMC article.
Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.
O' Donovan DH, Baker D, Ciotta G, Degorce SL, Demanze S, Dockerill M, Escudero-Ibarz L, Ireland L, Mao Y, Packer MJ, Robinson J, Scarfe G, Tang H, Valge-Archer V. O' Donovan DH, et al. Among authors: valge archer v. Bioorg Med Chem Lett. 2023 Nov 15;96:129518. doi: 10.1016/j.bmcl.2023.129518. Epub 2023 Oct 12. Bioorg Med Chem Lett. 2023. PMID: 37838344
24 results